The Structure and Functions of PRMT5 in Human Diseases

The Structure and Functions of PRMT5 in Human Diseases

Since the discovery of protein arginine methyltransferase 5 (PRMT5) and the resolution of its structure, an increasing number of papers have investigated and delineated the structural and functional role of PRMT5 in diseased conditions. PRMT5 is a type II arginine methyltransferase that catalyzes sy...

Full description

Bibliographic Details
Main Authors:	Aishat Motolani, Matthew Martin, Mengyao Sun, Tao Lu
Format:	Article
Language:	English
Published:	MDPI AG 2021-10-01
Series:	Life
Subjects:	PRMT5 cancer cardiovascular disease neurodegenerative diseases diabetes inflammation
Online Access:	https://www.mdpi.com/2075-1729/11/10/1074

Similar Items

Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue
by: Lakshmi Prabhu, et al.
Published: (2023-01-01)

The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLARL in human lung cancer cells
by: Mingyue Li, et al.
Published: (2019-02-01)

PRMT5 function and targeting in cancer
by: Hyungsoo Kim, et al.
Published: (2020-07-01)

Regulation of a PRMT5/NF-κB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer
by: Antja-Voy Hartley, et al.
Published: (2020-05-01)

Phosphorylation of the Regulators, a Complex Facet of NF-κB Signaling in Cancer
by: Aishat Motolani, et al.
Published: (2020-12-01)

Understanding the role of PRMT5 in neuroblastoma
by: Albayrak, G
Published: (2023)

Pan-cancer analysis identifies protein arginine methyltransferases PRMT1 and PRMT5 and their related signatures as markers associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma
by: Jia Wang, et al.
Published: (2023-12-01)

The Emerging Role of PRMT6 in Cancer
by: Zhixian Chen, et al.
Published: (2022-03-01)

Tadalafil increases the antitumor activity of 5-FU through inhibiting PRMT5-mediated glycolysis and cell proliferation in colorectal cancer
by: Yao Shen, et al.
Published: (2022-12-01)

PRMT5 promotes chemotherapy‐induced neuroendocrine differentiation in NSCLC
by: Qi Shen, et al.
Published: (2023-06-01)

The Role of PRMT5 in Immuno-Oncology
by: Yoshinori Abe, et al.
Published: (2023-03-01)

PRMT1 in human neoplasm: cancer biology and potential therapeutic target
by: Shiquan Shen, et al.
Published: (2024-02-01)

PRMT1 is an important factor for medulloblastoma cell proliferation and survival
by: Xiao Gu, et al.
Published: (2022-12-01)

PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma
by: Devendra Kumar, et al.
Published: (2023-12-01)

PRMT5 inhibition attenuates cartilage degradation by reducing MAPK and NF-κB signaling
by: Yonghui Dong, et al.
Published: (2020-09-01)

PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro
by: Wlaa Assi, et al.
Published: (2020-06-01)

PRMT5 regulates ovarian follicle development by facilitating Wt1 translation
by: Min Chen, et al.
Published: (2021-08-01)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
by: Coralie Poulard, et al.
Published: (2023-08-01)

PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
by: Michael K. C. Lee, et al.
Published: (2021-10-01)

Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
by: Nagendra K. Chaturvedi, et al.
Published: (2019-11-01)

PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells
by: Khuloud Bajbouj, et al.
Published: (2021-06-01)

The Wnt-target gene Dlk-1 is regulated by the Prmt5-associated factor Copr5 during adipogenic conversion
by: Conception Paul, et al.
Published: (2015-02-01)

The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression
by: Jianchao Zhang, et al.
Published: (2022-06-01)

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
by: Philip Vlummens, et al.
Published: (2022-06-01)

The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma
by: Tanner Wright, et al.
Published: (2021-01-01)

ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor
by: Zineb Mounir, et al.
Published: (2016-05-01)

TRAF6 Promotes PRMT5 Activity in a Ubiquitination-Dependent Manner
by: Liu Liu, et al.
Published: (2023-04-01)

PRMT5 regulates ATF4 transcript splicing and oxidative stress response
by: Magdalena M. Szewczyk, et al.
Published: (2022-05-01)

PRMT5 regulates the polysaccharide content by controlling the splicing of thaumatin-like protein in Ganoderma lucidum
by: Rui Liu, et al.
Published: (2023-12-01)

PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7
by: Congcong Cai, et al.
Published: (2021-05-01)

PRMT5 promotes progression of endometrioid adenocarcinoma via ERα and cell cycle signaling pathways
by: Shuyu Mei, et al.
Published: (2021-03-01)

Effect of PRMT5 Expression Knockdown on Proliferation, Invasion and Apoptosis of Gastric Cancer Cells and Its Mechanism
by: GUO Ping, et al.
Published: (2021-08-01)

Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer
by: Ziyan Yang, et al.
Published: (2022-04-01)

Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
by: Kelly Chiang, et al.
Published: (2018-05-01)

Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
by: Kavanya Feustel, et al.
Published: (2022-08-01)

Structure and Function of Protein Arginine Methyltransferase PRMT7
by: Levon Halabelian, et al.
Published: (2021-07-01)

PRMT5 Is Required for T Cell Survival and Proliferation by Maintaining Cytokine Signaling
by: Yukinori Tanaka, et al.
Published: (2020-04-01)

Effects of substrate modifications on the arginine dimethylation activities of PRMT1 and PRMT5
by: Melody D. Fulton, et al.
Published: (2022-01-01)

The crescent-like Golgi ribbon is shaped by the Ajuba/PRMT5/Aurora-A complex-modified HURP
by: Shao-Chih Chiu, et al.
Published: (2023-06-01)

A PRMT5 inhibitor protects against noise-induced hearing loss by alleviating ROS accumulation
by: Chang Liu, et al.
Published: (2022-09-01)